Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Aligned collagen is a prognostic signature for survival in human breast carcinoma.

Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedl A, Keely PJ.

Am J Pathol. 2011 Mar;178(3):1221-32. doi: 10.1016/j.ajpath.2010.11.076.

2.

Identification of prognostic collagen signatures and potential therapeutic stromal targets in canine mammary gland carcinoma.

Case A, Brisson BK, Durham AC, Rosen S, Monslow J, Buza E, Salah P, Gillem J, Ruthel G, Veluvolu S, Kristiansen V, Puré E, Brown DC, Sørenmo KU, Volk SW.

PLoS One. 2017 Jul 6;12(7):e0180448. doi: 10.1371/journal.pone.0180448. eCollection 2017.

3.

Collagen reorganization at the tumor-stromal interface facilitates local invasion.

Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ.

BMC Med. 2006 Dec 26;4(1):38.

4.

p53 as a marker of prognosis in African-American women with breast cancer.

Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S.

Ann Surg Oncol. 2010 May;17(5):1398-405. doi: 10.1245/s10434-009-0889-3. Epub 2010 Jan 5.

PMID:
20049641
5.

Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer.

Yousef GM, Scorilas A, Kyriakopoulou LG, Rendl L, Diamandis M, Ponzone R, Biglia N, Giai M, Roagna R, Sismondi P, Diamandis EP.

Clin Chem. 2002 Aug;48(8):1241-50.

6.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
7.

Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM.

Cancer. 2003 Feb 1;97(3):545-53.

9.

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.

Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

J Clin Oncol. 2010 Apr 10;28(11):1813-20. doi: 10.1200/JCO.2009.22.8775. Epub 2010 Mar 15.

PMID:
20231686
10.

The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer.

Rosin G, Hannelius U, Lindström L, Hall P, Bergh J, Hartman J, Kere J.

BMC Cancer. 2012 Feb 29;12:79. doi: 10.1186/1471-2407-12-79.

11.

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.

Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O.

Hum Pathol. 2012 Jan;43(1):23-30. doi: 10.1016/j.humpath.2011.04.011. Epub 2011 Jul 20.

PMID:
21777944
12.

Signal transducer and activator of transcription-5 activation and breast cancer prognosis.

Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H.

J Clin Oncol. 2004 Jun 1;22(11):2053-60.

PMID:
15169792
13.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

14.

[Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer].

Zhang B, Liu YX, Cao WF, Cao XC, Ning LS, Hao XS.

Zhonghua Bing Li Xue Za Zhi. 2008 Jul;37(7):471-6. Chinese.

PMID:
19035119
15.

Autophagy-related prognostic signature for breast cancer.

Gu Y, Li P, Peng F, Zhang M, Zhang Y, Liang H, Zhao W, Qi L, Wang H, Wang C, Guo Z.

Mol Carcinog. 2016 Mar;55(3):292-9. doi: 10.1002/mc.22278. Epub 2015 Jan 25.

PMID:
25620657
16.

Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.

Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O.

Breast Cancer Res Treat. 2010 Oct;123(3):733-45. doi: 10.1007/s10549-009-0672-y. Epub 2009 Dec 18.

PMID:
20020198
17.

Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer.

Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K.

Breast Cancer Res Treat. 2005 May;91(2):125-32.

PMID:
15868440
18.

Preoperative serum levels of matrix metalloproteinase-2 (MMP-2) and survival of breast cancer among Korean women.

Song N, Sung H, Choi JY, Han S, Jeon S, Song M, Lee Y, Park C, Park SK, Lee KM, Yoo KY, Noh DY, Ahn SH, Lee SA, Kang D.

Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1371-80. doi: 10.1158/1055-9965.EPI-12-0293. Epub 2012 May 25.

19.

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.

Klintman M, Bendahl PO, Grabau D, Lövgren K, Malmström P, Fernö M; South Sweden Breast Cancer Group.

Mod Pathol. 2010 Feb;23(2):251-9. doi: 10.1038/modpathol.2009.167. Epub 2009 Nov 20.

20.

GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.

Voduc D, Cheang M, Nielsen T.

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):365-73. doi: 10.1158/1055-9965.EPI-06-1090.

Supplemental Content

Support Center